These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 17391418)

  • 1. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
    Cipriano LE; Rupar CA; Zaric GS
    Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
    Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
    PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
    Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
    Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.
    Insinga RP; Laessig RH; Hoffman GL
    J Pediatr; 2002 Oct; 141(4):524-31. PubMed ID: 12378192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.
    Hamers FF; Rumeau-Pichon C
    BMC Pediatr; 2012 Jun; 12():60. PubMed ID: 22681855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.
    Autti-Rämö I; Mäkelä M; Sintonen H; Koskinen H; Laajalahti L; Halila R; Kääriäinen H; Lapatto R; Näntö-Salonen K; Pulkki K; Renlund M; Salo M; Tyni T
    Acta Paediatr; 2005 Aug; 94(8):1126-36. PubMed ID: 16188860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive cost-utility analysis of newborn screening strategies.
    Carroll AE; Downs SM
    Pediatrics; 2006 May; 117(5 Pt 2):S287-95. PubMed ID: 16735255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
    Norman R; Haas M; Chaplin M; Joy P; Wilcken B
    Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of expanded newborn screening in Texas.
    Tiwana SK; Rascati KL; Park H
    Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newborn screening for inborn errors of metabolism: a systematic review.
    Seymour CA; Thomason MJ; Chalmers RA; Addison GM; Bain MD; Cockburn F; Littlejohns P; Lord J; Wilcox AH
    Health Technol Assess; 1997; 1(11):i-iv, 1-95. PubMed ID: 9483156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario.
    Cipriano LE; Barth WH; Zaric GS
    BJOG; 2010 Aug; 117(9):1108-18. PubMed ID: 20560948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economics of tandem mass spectrometry screening of neonatal inherited disorders.
    Pandor A; Eastham J; Chilcott J; Paisley S; Beverley C
    Int J Technol Assess Health Care; 2006; 22(3):321-6. PubMed ID: 16984060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
    Tran K; Banerjee S; Li H; Noorani HZ; Mensinkai S; Dooley K
    Clin Biochem; 2007 Feb; 40(3-4):235-41. PubMed ID: 17222812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of tandem mass spectrometry screening in California.
    Feuchtbaum L; Cunningham G
    Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit analysis: newborn screening for inborn errors of metabolism in Lebanon.
    Khneisser I; Adib S; Assaad S; Megarbane A; Karam P
    J Med Screen; 2015 Dec; 22(4):182-6. PubMed ID: 26062758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands.
    van der Hilst CS; Derks TG; Reijngoud DJ; Smit GP; TenVergert EM
    J Pediatr; 2007 Aug; 151(2):115-20, 120.e1-3. PubMed ID: 17643759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tandem mass spectrometry as screening for inborn errors of metabolism].
    Campos H D
    Rev Med Chil; 2011 Oct; 139(10):1356-64. PubMed ID: 22286738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.
    Schoen EJ; Baker JC; Colby CJ; To TT
    Pediatrics; 2002 Oct; 110(4):781-6. PubMed ID: 12359795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.